SCHEMBL30004415

SCHEMBL30004415

CNc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNPH1 O43598 9/20 0.75
TAS1R3 Q7RTX0 2/20 0.75
TAS1R1 Q7RTX1 2/20 0.75
ADORA1 P30542 3/20 0.73
P2RY1 P47900 2/20 0.73
PRKAB2 O43741 1/20 0.73
TRPM2 O94759 1/20 0.73
LDHA P00338 1/20 0.73
ADRB2 P07550 1/20 0.73
FBP1 P09467 1/20 0.73
SRC P12931 1/20 0.73
P2RY2 P41231 1/20 0.73
PRKAG1 P54619 1/20 0.73
PRKAA2 P54646 1/20 0.73
PDE4D Q08499 1/20 0.73
KCNH2 Q12809 1/20 0.73
PRKAA1 Q13131 1/20 0.73
PDE3A Q14432 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
P2RY11 Q96G91 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4307198 1.00 DNPH1 (0.75) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL26067680 1.00 DNPH1 (0.75) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL14358309 0.99 DNPH1 (0.74) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL26067558 0.93 DNPH1 (0.66) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL26067580 0.93 DNPH1 (0.66) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL31396265 0.92 P2RX3 (0.77) DNPH1TAS1R3TAS1R1P2RY1TRPM2
SCHEMBL14358316 0.92 ADORA1 (0.77) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL18574268 0.92 P2RY1 (0.66) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL14929511 0.92 P2RY1 (0.66) DNPH1TAS1R3TAS1R1ADORA1P2RY1
SCHEMBL14946362 0.92 P2RY1 (0.66) DNPH1TAS1R3TAS1R1ADORA1P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120064427-A Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging 北京脑科学与类脑研究所 2025-05-30 CN claimed
CN-122017074-A Method for detecting phosphate-containing metabolite and application thereof 澳门科技大学 2026-05-12 CN disclosed
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 US disclosed
CN-120064427-A Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging 北京脑科学与类脑研究所 2025-05-30 CN disclosed
CN-118103711-A Single molecule identification with reactive heterogeneous nanopores 南京大学 2024-05-28 CN disclosed
WO-2023084013-A1 COMPOSITIONS COMPRISING MODIFIED RNA ENCODING VEGF-A AND METHODS OF USE MODERNATX, INC. (US) 2023-05-19 WO disclosed
WO-2023061985-A2 COMPOSITIONS COMPRISING MODIFIED RNA ENCODING VEGF-A AND METHODS OF USE MODERNATX, INC. (US) 2023-04-20 WO disclosed
WO-2023014974-A1 DOUBLE STRANDED MRNA VACCINES UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2023-02-09 WO disclosed
CN-112921014-B T7RNA polymerase mutant, mRNA, gene, expression vector and cell 左炽健 2023-01-06 CN disclosed
WO-2022241165-A2 COMPOSITIONS AND METHODS OF USE FOR MUTATED HOTAIR IN THE TREATMENT OF CANCERS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 DNPH1 2227/4885TAS1R3 3879/4885TAS1R1 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.